user
menu
letter
Sign InRegister
langEnglisharrow

Monoclonal Anti-Human Pertuzumab Antibody, Mouse IgG1 (4D9)

Cat. No. / Size
Price
Availability
Qty
HPB-Y2506-100ug
$315.00
In Stock - Delivery in 1-2 business days
HPB-Y2506-1mg
$2,079.00
In Stock - Delivery in 2-3 weeks
HPB-Y2506
Sub-Total :
$ 0
Customize Product Request Quote
Contact Us
Contact Us
Sub-Total:
$ 0
Request Quote
Product Details
Performance Data
Reviews & Citations
Resources
  • Product Details
  • Performance Data
  • Reviews & Citations
  • Important Statement
  • Resources
Source

Monoclonal Anti-Human Pertuzumab Antibody, Mouse IgG1 (4D9) (Cat. No. HPB-Y2506) is a mouse monoclonal antibody produced from a hybridoma generated by fusion of SP2/0 myeloma cells with mouse B lymphocytes.

Antibody Type

Hybridoma Monoclonal

Clone

4D9

Isotype

Mouse IgG1, Kappa

Host Species

Mouse

Specificity

Specifically recognizes Human Pertuzumab; This antibody is a neutralizing antibody.

Application
Application
Recommended Use
ELISA
0.2-2 μg/mL

* Recommended dilutions are for reference only. Optimal working concentrations may vary depending on your consumables, reagents, and assay conditions. We recommend optimizing for your specific system. No warranty is made regarding performance at any specific dilution.

Purification

Protein A purified.

Aggregation

Less than 5%, as determined by SEC-MALS.

Concentration

Please refer to the Certificate of Analysis (CoA).

Form

Liquid

Formulation

Supplied a 0.22 μm-filtered solution in PBS (pH 7.4), with trehalose as protectant.

Please contact us for customized product forms or formulations.

Storage

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:
  • The product MUST be stored at -70°C or lower upon receipt;
  • -70°C for 12 months under sterile conditions.
Notices

Product Specific Notices: For research use only.

ACRO Quality Management System

Background

Pertuzumab (brand name Perjeta), a recombinant humanized monoclonal antibody developed by Roche/Genentech, targets HER2’s extracellular dimerization domain. It is indicated for HER2-positive breast cancer (early neoadjuvant/adjuvant, metastatic) in combination with trastuzumab and chemotherapy. Its mechanism blocks HER2 heterodimerization, inhibiting downstream signaling and inducing apoptosis.